Condition: Immunotherapy Gastrict Cancer · Sponsor: Fujian Cancer Hospital
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
This description comes directly from the study's public registry record.
chen lu chuan, bachelor · 13905022862 · Luchuanchen@sina.cn
Ye Z sheng, Doctor of Medicine · 13950203076 · flyingengel@sina.cn
Always discuss trial participation with your own doctor first.
| Fujian cancer hospital | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05699655